AVXL - CIK 0001314052
The table below shows ANAVEX LIFE SCIENCES CORP.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $37.59M | $41.84M | $43.72M | $37.92M | $32.98M | $25.23M |
| SG&A | $13.82M |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $11.04M |
| $12.05M |
| $13.07M |
| $9.02M |
| $5.86M |
| Operating income | -$51.41M | -$52.88M | -$55.76M | -$50.99M | -$42.00M | -$31.09M |
| Income tax | - | - | - | - | - | - |
| Net income | -$46.38M | -$43.00M | -$47.51M | -$47.98M | -$37.91M | -$26.28M |
| EPS (diluted) | -$0.54 | -$0.52 | -$0.60 | -$0.62 | -$0.54 | - |